News Biocartis Group NV

Equities

BCART

BE0974281132

Real-time Euronext Bruxelles Other stock markets 11:35:06 2023-09-22 am EDT			5-day change	1st Jan Change
0.29 ^EUR	+1.05%		-.--%	-.--%

2023	Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress	CI
2023	Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)	Jan. 10	GL
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)	Jan. 10	GL
Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)	Jan. 10	AQ
Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion	Nov. 22	GL
Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting	Nov. 13	GL
Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors	23-10-31	GL
Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)	23-10-20	GL
Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress	23-10-20	CI
Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio	23-10-16	GL
Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio	23-10-16	AQ
Biocartis, APIS Assay Technologies to Commercialize Estrogen Receptor-positive Mutations Kit	23-10-12	MT
Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit	23-10-12	GL
Biocartis Group NV Announces Expansion of Its Collaboration with APIS Assay Technologies Ltd to Commercialize the APIS ESR1 Mutations Kit	23-10-12	CI
Press Release Biocartis Group NV: Disclosure of transparency notification	23-10-03	GL
Tragedies on Brussels stock market: these two former star stocks are now worth virtually 0 euros	23-09-26	AQ
Biocartis shareholders see their investment go up in smoke with planned stock market exit	23-09-26	AQ
Biocartis Winding Down Begins with Creditors' Takeover of Operating Units	23-09-26	MT
Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company	23-09-26	GL
Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization	23-09-26	GL
Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization	23-09-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biocartis Group NV

Equities

BCART

BE0974281132

Summary

Filters